Navigation Links
Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Date:10/22/2007

BOULDER, Colo., Oct. 22 /PRNewswire/ -- Sciona, Inc., a leader in the science of nutrigenetics, today announced the results of a pivotal study published by Nutrition Journal, which demonstrates substantial advances in long term weight management and blood glucose levels as a result of personalizing patients' diets based on their genetic information (nutrigenetics). In the first study to demonstrate the efficacy of applying nutrigenetics to long term weight management, researchers found significant improvement in long term (more than 300 days) weight management for individuals whose nutrient requirements were tailored to individual variations in the genes known to affect nutrient metabolism and transport. Each subject's genetic profile was developed by the use of Sciona's Mycellf Kit.

The comprehensive 3 year study examined 93 individuals with a history of weight loss failures. In an effort to answer whether the application of genetic information could improve sustained weight management, one test group was genetically screened for (24) separate variants in (19) individual genes specifically know to be related to metabolism. A second control group did not receive the genetic screening. The groups were matched on characteristics such as age, gender, frequency of clinical visits and Body Mass Index (BMI), during their initial clinical visit. After monitoring patients between the fixed ranges of 100 - 300 days, the BMI and the fasting blood glucose levels were compared and contrasted within the test population.

Results conclusively showed that after 300 days, individuals in the genetic testing group were more likely to have maintained weight reduction and reduced glucose levels than those of the control group, which had not been genetically screened. In the final analysis, 73% of those in the nutrigenetic group maintained weight reduction compared to only 32% of those in the control group. Among patients with a fasting blood glucose of greater than 100 mg/dl, 57% of the nutrigenetic group, compared to only 25% of the control group had levels reduced to less that 100 mg/dl after more than 90 days of weight management therapy. These results reflected a return to normal blood glucose levels from pre-diabetic levels in the nutrigenetic group, based on a genetically tailored diet and exercise program.

Sciona's Chief Science Officer, Dr. Rosalynn Gill stated, "We are delighted with the results of this study given the global health problems associated with clinical obesity and diabetes." Dr. Gill went on to note that according to the US Department of Health and Human Services, the total cost of obesity, including those illnesses associated with obesity such as type II diabetes, coronary heart disease, and hypertension in the year 2000 was approximately $117 billion dollars. Sciona's CEO, Peter Vitulli, stated, "Sciona's Mycellf genetic testing kit allows an individual to learn how to personalize their nutrition and lifestyle to match their genes, which gives them a revolutionary gene-based road map to better health and a longer life." Study coordinator, Dr. Ioannis Arkadianos, stated, "The results of this clinical study featuring the application of nutrigenetics clearly demonstrates that using genetic information is critical in helping people optimize their health. As a clinician, it is gratifying to be able to apply the information regarding an individual's inherited genetic code to help us to understand how each person's body works. We finally have the tools that enable health care professionals such as myself to determine which nutrition and exercise protocols will get results and what nutrigenetic interventions will promote longevity. Just like fingerprints, no two individuals are the same and so we are now able to personalize your health based on your DNA."

Summary: Tailoring a weight loss program to individuals' unique genetic profiles, even in a group with a history of prior weight loss failures, resulted in significant improvements in better compliance, greater motivation, and improved effectiveness when measured by weight reduction, BMI, and glucose levels, in a long term study, over 300 days.

About The Study

Patients with a history of unsuccessful attempts at weight loss attending a weight management clinic in Athens, Greece were offered a nutrigenetic test screening 24 variations in 19 genes involved in metabolism. The case histories of 50 "nutrigenetic" patients were compared to those of 43 patients in the non-tested group attending the same clinic. All patients followed a traditional weight management program involving a low glycemic index Mediterranean diet, recommended exercise routines and regular follow-up visits in the clinic. The dietary program of the patients in the nutrigenetic group was modified from the standard diet based on the genetic results of each patient. The patients participating in the study were blinded to the clinicians. After 300 days, the patients following the nutrigenetically tailored diet and exercise programs demonstrated better long-term BMI reduction and improvements in blood fasting glucose. Key contributors to the study included the Twin Research Unit, King's College London, UK and the Biomedical Engineering Laboratory, National Technical University of Athens, Greece.

About Sciona, Inc.

Sciona, an international company founded in 2000 to provide personalized health and nutrition recommendations based on an individual's diet, lifestyle and unique genetic profile, has created a powerful set of tools utilizing their proprietary Rules Engine which allows consumers to harness the scientific information uncovered in the landmark Human Genome Project. For more information, visit Sciona, Inc. at http://www.Sciona.com, or the Mycellf product website at http://www.Mycellf.com.


'/>"/>
SOURCE Sciona, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):